p53-based gene therapy of ovarian cancer: magic bullet?

Prognostic gene expression signature for high-grade serous ovarian cancer.

Annals of oncology : official journal of the European Society for Medical Oncology·2020

Intraperitoneal chemotherapy following neoadjuvant chemotherapy and optimal interval tumor reductive surgery for advanced ovarian cancer.

Gynecologic oncology·2020

Linking genomic reorganization to tumor initiation via the giant cell cycle.

Oncogenesis·2016

Gankyrin facilitates follicle-stimulating hormone-driven ovarian cancer cell proliferation through the PI3K/AKT/HIF-1α/cyclin D1 pathway.

Oncogene·2015

ARHI (DIRAS3)-mediated autophagy-associated cell death enhances chemosensitivity to cisplatin in ovarian cancer cell lines and xenografts.

Cell death & disease·2015

ARHI (DIRAS3) induces autophagy in ovarian cancer cells by downregulating the epidermal growth factor receptor, inhibiting PI3K and Ras/MAP signaling and activating the FOXo3a-mediated induction of Rab7.

Cell death and differentiation·2014

Planning and feasibility of phase III surgical trials in gynecologic oncology.

Gynecologic oncology·2026

Minimally invasive surgery without a uterine manipulator versus open radical hysterectomy for early-stage cervical cancer: A retrospective propensity-score-matched single-center cohort study.

Gynecologic oncology·2026

Mutated p53 results in altered type I interferon pathway expression and signaling in endometrial cancer.

Gynecologic oncology·2026

Molecular groups predict response to fertility-sparing treatment of endometrial carcinoma: a systematic review and metanalysis.

Gynecologic oncology·2026

Molecular characterization of NSMP endometrial cancer and its relevance for treatment.

Gynecologic oncology·2026

High rates of venous thromboembolism in endometrial cancer patients requiring systemic therapy: an opportunity for risk assessment and intervention.

Gynecologic oncology·2026

Radium-223 decreases PD-L1 expression in bone metastases: A study with [89Zr]Zr-atezolizumab PET and immunohistological correlation.

European journal of nuclear medicine and molecular imaging·2026

Radiopharmaceutical Combination Therapies in Advanced Prostate Cancer.

Journal of nuclear medicine : official publication, Society of Nuclear Medicine·2026

Heterozygous germline mutations in MSH3, and probably MLH3, act as classical tumour suppressors, leading to excess somatic deletion mutations, signature ID4 and increased colorectal cancer risk.

Gut·2026

Bridging preclinical and clinical efficacy of SIK2/SIK3 inhibition in inflammatory bowel disease through integrated murine, patient-derived models, and phase 2a trial-based analyses.

Journal of Crohn's & colitis·2026

Engineered nano-delivery platforms targeting ferroptosis-evasion pathways to reverse tumor drug resistance.

Biochimica et biophysica acta. Reviews on cancer·2026

Antibody therapeutics: A new era for EGFR-mutant NSCLC treatment.

Biochimica et biophysica acta. Reviews on cancer·2026

Related Experiment Videos

p53-based gene therapy of ovarian cancer: magic bullet?

Related Concept Videos

Prognostic gene expression signature for high-grade serous ovarian cancer.

Intraperitoneal chemotherapy following neoadjuvant chemotherapy and optimal interval tumor reductive surgery for advanced ovarian cancer.

Linking genomic reorganization to tumor initiation via the giant cell cycle.

Gankyrin facilitates follicle-stimulating hormone-driven ovarian cancer cell proliferation through the PI3K/AKT/HIF-1α/cyclin D1 pathway.

ARHI (DIRAS3)-mediated autophagy-associated cell death enhances chemosensitivity to cisplatin in ovarian cancer cell lines and xenografts.

ARHI (DIRAS3) induces autophagy in ovarian cancer cells by downregulating the epidermal growth factor receptor, inhibiting PI3K and Ras/MAP signaling and activating the FOXo3a-mediated induction of Rab7.

Planning and feasibility of phase III surgical trials in gynecologic oncology.

Minimally invasive surgery without a uterine manipulator versus open radical hysterectomy for early-stage cervical cancer: A retrospective propensity-score-matched single-center cohort study.

Mutated p53 results in altered type I interferon pathway expression and signaling in endometrial cancer.

Molecular groups predict response to fertility-sparing treatment of endometrial carcinoma: a systematic review and metanalysis.

Molecular characterization of NSMP endometrial cancer and its relevance for treatment.

High rates of venous thromboembolism in endometrial cancer patients requiring systemic therapy: an opportunity for risk assessment and intervention.

Radium-223 decreases PD-L1 expression in bone metastases: A study with [89Zr]Zr-atezolizumab PET and immunohistological correlation.

Radiopharmaceutical Combination Therapies in Advanced Prostate Cancer.

Heterozygous germline mutations in MSH3, and probably MLH3, act as classical tumour suppressors, leading to excess somatic deletion mutations, signature ID4 and increased colorectal cancer risk.

Bridging preclinical and clinical efficacy of SIK2/SIK3 inhibition in inflammatory bowel disease through integrated murine, patient-derived models, and phase 2a trial-based analyses.

Engineered nano-delivery platforms targeting ferroptosis-evasion pathways to reverse tumor drug resistance.

Antibody therapeutics: A new era for EGFR-mutant NSCLC treatment.

Related Experiment Videos

p53-based gene therapy of ovarian cancer: magic bullet?

Related Concept Videos

Related Articles